ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 191 filers reported holding ALLOGENE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.89 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $414,126 | -39.3% | 130,639 | -4.8% | 0.02% | -37.8% |
Q2 2023 | $682,043 | +10.8% | 137,232 | +10.1% | 0.04% | -2.6% |
Q1 2023 | $615,578 | +426.1% | 124,611 | +1118.2% | 0.04% | +442.9% |
Q2 2022 | $117,000 | +14.7% | 10,229 | -9.0% | 0.01% | +75.0% |
Q1 2022 | $102,000 | -45.2% | 11,243 | -10.0% | 0.00% | -33.3% |
Q4 2021 | $186,000 | -48.2% | 12,492 | -10.6% | 0.01% | -50.0% |
Q3 2021 | $359,000 | +3.2% | 13,980 | +4.7% | 0.01% | 0.0% |
Q2 2021 | $348,000 | -25.8% | 13,349 | +0.4% | 0.01% | -33.3% |
Q1 2021 | $469,000 | +27.4% | 13,294 | -8.9% | 0.02% | +12.5% |
Q4 2020 | $368,000 | -25.7% | 14,586 | +11.1% | 0.02% | -36.0% |
Q3 2020 | $495,000 | -23.4% | 13,132 | -12.9% | 0.02% | -30.6% |
Q2 2020 | $646,000 | +224.6% | 15,078 | +47.7% | 0.04% | +140.0% |
Q1 2020 | $199,000 | -46.5% | 10,211 | -28.6% | 0.02% | -6.2% |
Q4 2019 | $372,000 | +8.5% | 14,300 | +13.6% | 0.02% | -5.9% |
Q3 2019 | $343,000 | – | 12,588 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
VV Manager LLC | 1,798,163 | $76,997,000 | 67.53% |
Wildcat Capital Management, LLC | 1,515,524 | $64,895,000 | 22.42% |
TPG Group Holdings (SBS) Advisors, Inc. | 19,716,306 | $844,252,000 | 14.91% |
REGENTS OF THE UNIVERSITY OF CALIFORNIA | 1,279,281 | $54,779,000 | 7.69% |
Coastal Bridge Advisors, LLC | 463,117 | $19,831,000 | 6.33% |
DSAM Partners (London) Ltd | 235,098 | $10,067,000 | 2.63% |
Casdin Capital, LLC | 625,000 | $26,763,000 | 1.58% |
Alpine Global Management, LLC | 150,000 | $6,423,000 | 1.13% |
Perceptive Advisors | 1,543,790 | $66,105,000 | 1.07% |
Avoro Capital Advisors LLC | 1,128,594 | $48,326,000 | 0.96% |